Literature DB >> 29427585

Vildagliptin Significantly Increases the Risk of Bullous Pemphigoid: A Finnish Nationwide Registry Study.

Outi Varpuluoma1, Anna-Kaisa Försti1, Jari Jokelainen2, Miia Turpeinen3, Markku Timonen4, Laura Huilaja1, Kaisa Tasanen5.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 29427585     DOI： 10.1016/j.jid.2018.01.027

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN： 0022-202X            Impact factor:   8.551


× No keyword cloud information.
  30 in total

1.  Is there an association between dipeptidyl peptidase-4 inhibitors and autoimmune disease? A population-based study.

Authors:  Khalaf Kridin; Kyle Amber; Mogher Khamaisi; Doron Comaneshter; Erez Batat; Arnon D Cohen
Journal:  Immunol Res       Date:  2018-06       Impact factor: 2.829

2.  Association of Dipeptidyl Peptidase 4 Inhibitor Use With Risk of Bullous Pemphigoid in Patients With Diabetes.

Authors:  Seon Gu Lee; Hee Jung Lee; Moon Soo Yoon; Dong Hyun Kim
Journal:  JAMA Dermatol       Date:  2019-02-01       Impact factor: 10.282

3.  [85-year-old male with cutaneous blisters : Preparation for the medical specialist examination: Part 25].

Authors:  Mareike Witte; Enno Schmidt; Ralf Ludwig
Journal:  Hautarzt       Date:  2018-11       Impact factor: 0.751

4.  Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients.

Authors:  Khalaf Kridin; Reuven Bergman
Journal:  JAMA Dermatol       Date:  2018-10-01       Impact factor: 10.282

5.  Association Between Medication Use and Bullous Pemphigoid: A Systematic Review and Meta-analysis.

Authors:  Sian-De Liu; Wei-Ti Chen; Ching-Chi Chi
Journal:  JAMA Dermatol       Date:  2020-08-01       Impact factor: 10.282

6.  Clinical, Laboratory and Histological Features of Dipeptidyl Peptidase-4 Inhibitor Related Noninflammatory Bullous Pemphigoid.

Authors:  Ágnes Kinyó; Anita Hanyecz; Zsuzsanna Lengyel; Dalma Várszegi; Péter Oláh; Csaba Gyömörei; Endre Kálmán; Tímea Berki; Rolland Gyulai
Journal:  J Clin Med       Date:  2021-04-28       Impact factor: 4.241

7.  Livedoid and Purpuric Skin Eruptions Associated With Coagulopathy in Severe COVID-19.

Authors:  Caren Droesch; Mytrang Hoang Do; Maria DeSancho; Eun-Ju Lee; Cynthia Magro; Joanna Harp
Journal:  JAMA Dermatol       Date:  2020-09-01       Impact factor: 10.282

8.  A Systematic Review of Drug-Induced Pemphigoid.

Authors:  Matthew J Verheyden; Asli Bilgic; Dédée F Murrell
Journal:  Acta Derm Venereol       Date:  2020-08-17       Impact factor: 3.875

Review 9.  Bullous Autoimmune Dermatoses–Clinical Features, Diagnostic Evaluation, and Treatment Options.

Authors:  Nina van Beek; Detlef Zillikens; Enno Schmidt
Journal:  Dtsch Arztebl Int       Date:  2021-06-18       Impact factor: 8.251

10.  Increased Risk of Squamous Cell Carcinoma of the Skin and Lymphoma Among 5,739 Patients with Bullous Pemphigoid: A Swedish Nationwide Cohort Study.

Authors:  Zeyad Albadri; Kristofer Thorslund; Henrike Häbel; Oliver Seifert; Carina Grönhagen
Journal:  Acta Derm Venereol       Date:  2020-10-14       Impact factor: 3.875
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.